The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation

Aguilar, 2007, Vaccine adjuvants revisited, Vaccine, 25, 3752, 10.1016/j.vaccine.2007.01.111 Reed, 2009, New horizons in adjuvants for vaccine development, Trends Immunol, 30, 23, 10.1016/j.it.2008.09.006 Dekker, 2008 Gupta, 1998, Aluminum compounds as vaccine adjuvants, Adv Drug Deliv Rev, 32, 155, 10.1016/S0169-409X(98)00008-8 Cain, 2013, Disparate adjuvant properties among three formulations of “alum”, Vaccine, 31, 653, 10.1016/j.vaccine.2012.11.044 Purcell, 2007, More than one reason to rethink the use of peptides in vaccine design, Nat Rev Drug Discov, 6, 404, 10.1038/nrd2224 Jennings, 2008, Coming of age of virus-like particle vaccines, Biol Chem, 389, 521, 10.1515/BC.2008.064 Tissot, 2010, Versatile virus-like particle carrier for epitope based vaccines, PLoS One, 5, e9809, 10.1371/journal.pone.0009809 Kaba, 2009, A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria, J Immunol, 183, 7268, 10.4049/jimmunol.0901957 Kaba, 2012, Protective antibody and CD8(+) T-Cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine, PLoS One, 7, e48304, 10.1371/journal.pone.0048304 Bershteyn, 2012, Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine, J Control Release, 157, 354, 10.1016/j.jconrel.2011.07.029 Fifis, 2004, Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice, Vaccine, 23, 258, 10.1016/j.vaccine.2004.05.022 Reddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat Biotechnol, 25, 1159, 10.1038/nbt1332 Ulery, 2011, Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases, PLoS One, 6, e17642, 10.1371/journal.pone.0017642 Rudra, 2012, Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope, Biomaterials, 33, 6476, 10.1016/j.biomaterials.2012.05.041 Rudra, 2012, Modulating adaptive immune responses to peptide self-assemblies, ACS Nano, 6, 1557, 10.1021/nn204530r Rudra, 2010, A self-assembling peptide acting as an immune adjuvant, Proc Natl Acad Sci U S A, 107, 622, 10.1073/pnas.0912124107 Moon, 2012, Engineering nano- and microparticles to tune immunity, Adv Mater, 24, 3724, 10.1002/adma.201200446 Bachmann, 2010, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat Rev Immunol, 10, 787, 10.1038/nri2868 Reddy, 2006, Targeting dendritic cells with biomaterials: developing the next generation of vaccines, Trends Immunol, 27, 573, 10.1016/j.it.2006.10.005 Sharp, 2009, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome, Proc Natl Acad Sci U S A, 106, 870, 10.1073/pnas.0804897106 Petersen, 2011, Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants, Biomaterials, 32, 6815, 10.1016/j.biomaterials.2011.05.063 Torres, 2011, Polyanhydride microparticles enhance dendritic cell antigen presentation and activation, Acta Biomater, 7, 2857, 10.1016/j.actbio.2011.03.023 Ulery, 2011, Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants, Sci Rep, 1, 198, 10.1038/srep00198 Lewis, 2012, Microparticle surface modifications targeting dendritic cells for non-activating applications, Biomaterials, 33, 7221, 10.1016/j.biomaterials.2012.06.049 Huntimer, 2013, Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery, Adv Healthc Mater, 2, 369, 10.1002/adhm.201200181 Jung, 2009, Co-assembling peptides as defined matrices for endothelial cells, Biomaterials, 30, 2400, 10.1016/j.biomaterials.2009.01.033 Jung, 2008, Modulating the mechanical properties of self-assembled peptide hydrogels via native chemical ligation, Biomaterials, 29, 2143, 10.1016/j.biomaterials.2008.01.008 Thomas, 2006, An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses, Proc Natl Acad Sci U S A, 103, 2764, 10.1073/pnas.0511185103 Marichal, 2011, DNA released from dying host cells mediates aluminum adjuvant activity, Nat Med, 17, 996, 10.1038/nm.2403 Kool, 2008, Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells, J Exp Med, 205, 869, 10.1084/jem.20071087 HogenEsch, 2013, Mechanism of immunopotentiation and safety of aluminum adjuvants, Front Immunol, 3, 406, 10.3389/fimmu.2012.00406 Goto, 1997, Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties, Vaccine, 15, 1364, 10.1016/S0264-410X(97)00054-6 Seubert, 2011, Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88, Proc Natl Acad Sci U S A, 108, 11169, 10.1073/pnas.1107941108 McKee, 2009, Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity, J Immunol, 183, 4403, 10.4049/jimmunol.0900164 Calabro, 2011, Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes, Vaccine, 29, 1812, 10.1016/j.vaccine.2010.12.090 Crotty, 2011, Follicular helper CD4 T cells (T-fh), Annu Rev Immunol, 29, 621, 10.1146/annurev-immunol-031210-101400 Huang, 2012, A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy, J Am Chem Soc, 134, 8730, 10.1021/ja211725s Jackson, 2002, The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer, Curr Drug Targets, 3, 175, 10.2174/1389450024605436 Lanzavecchia, 2007, Toll-like receptors and innate immunity in B-cell activation and antibody responses, Curr Opin Immunol, 19, 268, 10.1016/j.coi.2007.04.002 Malyala, 2008, Endotoxin limits in formulations for preclinical research, J Pharm Sci, 97, 2041, 10.1002/jps.21152 Ohmit, 2011, Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection, J Infect Dis, 204, 1879, 10.1093/infdis/jir661 Banzhoff, 2008, MF59 (R)-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis, Influenza Other Respir Viruses, 2, 243, 10.1111/j.1750-2659.2008.00059.x Vogel, 2009, Emulsion-based adjuvants for influenza vaccines, Exp Rev Vaccines, 8, 483, 10.1586/erv.09.5 Baldwin, 2009, Enhanced humoral and Type 1 cellular immune responses with Fluzone (R) adjuvanted with a synthetic TLR4 agonist formulated in an emulsion, Vaccine, 27, 5956, 10.1016/j.vaccine.2009.07.081 Clegg, 2012, Adjuvant solution for pandemic influenza vaccine production, Proc Natl Acad Sci U S A, 109, 17585, 10.1073/pnas.1207308109 Coler, 2011, Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant, PLoS One, 6, e16333, 10.1371/journal.pone.0016333 Skwarczynski, 2011, Peptide-based subunit nanovaccines, Curr Drug Deliv, 8, 282, 10.2174/156720111795256192 Swartz, 2012, Engineering approaches to immunotherapy, Sci Transl Med, 4, 148rv9, 10.1126/scitranslmed.3003763 Malyala, 2008, The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles, J Pharm Sci, 97, 1155, 10.1002/jps.21065 Moon, 2012, Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand T-fh cells and promote germinal center induction, Proc Natl Acad Sci U S A, 109, 1080, 10.1073/pnas.1112648109 De Geest, 2012, Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection, ACS Nano, 6, 2136, 10.1021/nn205099c Collier, 2008, Modular self-assembling biomaterials for directing cellular responses, Soft Matter, 4, 2310, 10.1039/b805563g Jung, 2011, Multifactorial optimization of endothelial cell growth using modular synthetic extracellular matrices, Integr Biol, 3, 185, 10.1039/c0ib00112k Thomas, 2011, Engineering complement activation on polypropylene sulfide vaccine nanoparticles, Biomaterials, 32, 2194, 10.1016/j.biomaterials.2010.11.037 Black, 2012, Self-assembled peptide amphiphile micelles containing a cytotoxic T-Cell epitope promote a protective immune response in vivo, Adv Mater, 24, 3845, 10.1002/adma.201200209 Hirosue, 2010, Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation, Vaccine, 28, 7897, 10.1016/j.vaccine.2010.09.077